When the Boston Celtics selected Len Bias with the second overall pick in the 1986 NBA draft, he called it a dream come true. Two days later, the 22-year-old was dead after a cocaine-induced cardiac event. The national outcry that followed propelled the Anti-Drug Abuse Act, which President Ronald Reagan signed on Oct. 27, 1986, promising it was not meant to fill prisons with drug users but to help them quit.
Four decades on, the law's legacy is starkly lopsided: the penalties it created are permanent federal law, while the treatment it promised has been subject to the whims of annual appropriations. That imbalance, say policy experts, is the law's most enduring and damaging feature.
Rushed Legislation, Lasting Disparities
The mandatory minimums were drafted in a frenzy. Eric Sterling, then counsel to the House Judiciary Committee, recalled that the thresholds were added days before the August recess, with no hearings on the drug quantities that triggered them. The result was a 100-to-1 sentencing disparity between crack and powder cocaine: five grams of crack—about the weight of a nickel—carried the same five-year minimum as 500 grams of powder, over a pound. The U.S. Sentencing Commission later found no legislative record explaining that ratio, and a House committee eventually acknowledged that Bias had used powder cocaine, not crack.
The costs were borne disproportionately by Black Americans. In 1993, 88% of those convicted of federal crack trafficking were Black. By 2011, the federal prison population had tripled in two decades, with mandatory minimums a key driver. Congress has since narrowed the gap, but an 18-to-1 ratio remains in federal law.
Treatment: The Broken Promise
The law's title promised to expand federal support for treatment and rehabilitation, but that support required annual funding. Ten weeks after signing, the Reagan administration requested no new money for drug treatment, prompting Rep. Benjamin Gilman (R-N.Y.) to call the cuts “appalling.” That pattern has persisted. In 2025, 84% of the 47.2 million Americans who needed substance use treatment did not receive it, according to federal survey data.
The deadliest consequence comes after incarceration. A study of people released from North Carolina prisons found they died of opioid overdoses at 40 times the state's general population rate in their first two weeks home. Yet federal law generally bars Medicaid from paying for care during incarceration, forcing states to seek waivers to start treatment before release. In September, federal officials cut the maximum pre-release window for future adult waivers from 90 days to 60—without a vote.
What Congress Can Do Now
The bipartisan Reentry Act would let every state cover the last 30 days before release without a waiver, creating a floor that no agency could shrink. Lawmakers should include it in the year-end spending package before current funding expires Dec. 11. They should also resist the president's proposal to fold addiction treatment grants into a single block grant, which could dilute funding.
Congress has shown it can act decisively on treatment. In 2024, it made permanent Medicaid's coverage of medications for opioid use disorder. Extending that permanence to reentry care would be a fitting corrective to the 1986 law's imbalance. As the nation marks 40 years of punitive policy, the question is whether lawmakers will finally match the speed they showed after Bias's death with the same urgency for treatment.
